Anti-osteoporosis mechanism of Panax quiquefolium L. based on zebrafish model and metabonomics
10.16438/j.0513-4870.2022-1293
- VernacularTitle:基于斑马鱼模型和代谢组学技术的西洋参抗骨质疏松作用机制研究
- Author:
Yue-zi QIU
1
,
2
;
Chuan-sen WANG
1
,
2
;
Feng-hua XU
3
;
Xuan-ming ZHANG
1
,
2
;
Li-zhen WANG
1
,
2
;
Pei-hai LI
1
,
2
;
Ke-chun LIU
1
,
2
;
Peng-fei TU
4
;
Hou-wen LIN
5
;
Shan-shan ZHANG
1
,
2
;
Xiao-bin LI
1
,
2
Author Information
1. Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China
2. Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Jinan 250103, China
3. School of Basic Medical Sciences, Qingdao University, Qingdao 266000, China
4. School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
5. Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
- Publication Type:Research Article
- Keywords:
italic>Panax quiquefolium L.;
metabonomics;
zebrafish;
osteoporosis;
mechanism of action
- From:
Acta Pharmaceutica Sinica
2023;57(7):1894-1903
- CountryChina
- Language:Chinese
-
Abstract:
In this study, we investigated the anti-osteoporotic activity and mechanism of action of extract of Panax quiquefolium L. based on zebrafish model combined with metabolomics technology. A zebrafish model of prednisolone-induced osteoporosis was used to compare the anti-osteoporotic activity of Panax quiquefolium L., and the expression of osteoblast-associated genes and osteoclast-associated genes in zebrafish was detected by quantitative real-time PCR (qRT-PCR), using bone fluorescence area and fluorescence density as evaluation indexes. Metabolomics based on ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) was used to explore the change patterns of biomarkers and the metabolic pathways affected. The results showed that the 50% ethanol extracts of Panax quiquefolium L. from Jilin, Canada, Wenden and the United States can significantly improve the bone fluorescence area of zebrafish compared with model group. Furthermore, four sources 50% ethanol extracts of Panax quiquefolium L. except United States also can significantly improve the bone fluorescence density of zebrafish. In addition, PCR showed that extract of Panax quiquefolium L. can significantly up-regulated the expression of vitamin D receptor b (vdrb), collagen type I α2 (col1a2) and cysteine-rich acidic secreted protein (sparc) genes, and down-regulated the expression of matrix metalloproteinase 9 (mmp9), anti-tartrase acid phosphatase (trap) and cathepsin K (ctsk) genes. Metabolomic analysis identified 24 key differential metabolites. Furthermore, pathway analysis showed that Panax quiquefolium L. could regulate the levels of 10 key biomarkers by participating in purine metabolism, tricarboxylic acid cycle and pentose phosphate metabolism and improve the osteoporosis status of zebrafish. This study preliminically revealed the anti-osteoporosis mechanism of 50% ethanol extract from Panax quiquefolium L. through multi-component, multi-target and multi-pathway and also provides theoretical basis for clinical development and utilization of anti-osteoporosis products of Panax quiquefolium L. This experiment was approved by the Experimental Animal Welfare Ethics Committee of the Institute of Biology, Shandong Academy of Sciences (approval number: SWS20181002).
